{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12300","value":"88800"},{"groupId":"OG001","spread":"38800","value":"116000"},{"groupId":"OG002","spread":"85700","value":"212000"},{"groupId":"OG003","spread":"49600","value":"383000"},{"groupId":"OG004","spread":"120000","value":"638000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG005","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg"}],"paramType":"MEAN","populationDescription":"PK -evaluable set included treated participants with adequate blood sampling to estimate at least one PK parameter. Here, \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Part 4: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1","title":"Part 4: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621","type":"SECONDARY","unitOfMeasure":"Nanogram*hour per milliliter"}